Race Oncology on RC220 ethics, 2024 milestones and 2025 outlook
Published: 04:59 05 Dec 2024 GMT
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO and managing director Daniel Tillett talks with Proactive’s Tylah Tully about the company’s recent achievements, including submitting an ethics approval application for its Phase 1 RC220 clinical trial.
He explained the importance of this milestone, as it marks the kickoff of a clinical program for a newly reformulated cancer drug.
Tillett elaborated on the drug’s history, noting how past challenges were resolved by reformulating it to eliminate previous obstacles.
He highlighted its dual potential to combat cancer effectively and protect the cardiovascular system from chemotherapy-induced damage.
"The results of that can be life-changing," Tillett remarked, emphasising the transformative potential for patient outcomes.
Reflecting on 2024, Tillett noted the company’s success in manufacturing the drug to GMP standards, completing GLP safety studies and setting up the framework for clinical trials.
Looking ahead, he outlined goals for 2025, including demonstrating the drug’s safety and proving its cardiovascular protection capabilities in clinical trials.
